tosufloxacin has been researched along with Recrudescence in 2 studies
tosufloxacin: quinolone anti-infective agent; structure given in first source
tosufloxacin : A racemate comprising equimolar amounts of (R)- and (S)-tosufloxacin.
7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 3-aminopyrrolidin-1-yl substituents at positions 1, 6 and 7 respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Symptomatic nontyphoid salmonella enterocolitis patients were treated with tosufloxacin (TFLX) at oral doses of 150 mg three times a day for 5 to 7 days, but bacterial relapse without symptoms occurred in 85% of the patients within 15 days after the cessation of therapy." | 7.71 | Salmonella excretion after cessation of tosufloxacin therapy in acute nontyphoid salmonella enterocolitis. ( Kimura, K; Ohnishi, K, 2001) |
| "Forty five patients with complicated urinary tract infections were treated with tosufloxacin (TFLX) in the initial antibacterial treatment." | 5.07 | [Study on clinical effects of tosufloxacin (TFLX) and the long-term low dose therapy for the prophylaxis of recurrent urinary tract infection]. ( Arima, K; Hoshina, A; Kawamura, J; Nagano, M; Nakano, S; Saitou, K; Sakurai, M; Satani, H; Sugimura, Y; Tajima, K, 1994) |
| "Symptomatic nontyphoid salmonella enterocolitis patients were treated with tosufloxacin (TFLX) at oral doses of 150 mg three times a day for 5 to 7 days, but bacterial relapse without symptoms occurred in 85% of the patients within 15 days after the cessation of therapy." | 3.71 | Salmonella excretion after cessation of tosufloxacin therapy in acute nontyphoid salmonella enterocolitis. ( Kimura, K; Ohnishi, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sakurai, M | 1 |
| Sugimura, Y | 1 |
| Arima, K | 1 |
| Kawamura, J | 1 |
| Saitou, K | 1 |
| Tajima, K | 1 |
| Nakano, S | 1 |
| Satani, H | 1 |
| Nagano, M | 1 |
| Hoshina, A | 1 |
| Ohnishi, K | 1 |
| Kimura, K | 1 |
1 trial available for tosufloxacin and Recrudescence
| Article | Year |
|---|---|
[Study on clinical effects of tosufloxacin (TFLX) and the long-term low dose therapy for the prophylaxis of recurrent urinary tract infection].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Female; Fluoroquinolones; Humans; Male; Middl | 1994 |
1 other study available for tosufloxacin and Recrudescence
| Article | Year |
|---|---|
Salmonella excretion after cessation of tosufloxacin therapy in acute nontyphoid salmonella enterocolitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Enterocolitis; Feces; Female; | 2001 |